Cargando…

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall survival (OS). Sorafenib plus doxorubicin combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Dika, Imane, Capanu, Marinela, Chou, Joanne F., Harding, James J., Ly, Michele, Hrabovsky, Anna D., Do, Richard K.G., Shia, Jinru, Millang, Brittanie, Ma, Jennifer, O’Reilly, Eileen M., Abou‐Alfa, Ghassan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571806/ https://www.ncbi.nlm.nih.gov/pubmed/32841541 http://dx.doi.org/10.1002/cam4.3389

Ejemplares similares

Treatment options after sorafenib failure in patients with hepatocellular carcinoma
por: Dika, Imane El, et al.
Publicado: (2017)

Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States
por: Zou, Chenhui, et al.
Publicado: (2021)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
por: Abou-Alfa, Ghassan K., et al.
Publicado: (2022)

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018)

Hepatocellular carcinoma, novel therapies on the horizon
por: El Dika, Imane, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior
por: Sahin, Ibrahim H., et al.
Publicado: (2018)

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2015)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery
por: Babos, György, et al.
Publicado: (2020)

Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines
por: Yang, Ya-Ting, et al.
Publicado: (2022)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
por: Wang, Pusen, et al.
Publicado: (2020)

FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p–CCNG1 interaction network
por: Liu, Yan-Tong, et al.
Publicado: (2020)

Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles
por: Babos, György, et al.
Publicado: (2018)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma
por: Ito, Yasuhiro, et al.
Publicado: (2017)

Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
por: Samawi, Haider H., et al.
Publicado: (2018)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
por: Huh, Ki-Young, et al.
Publicado: (2021)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
por: Trédan, Olivier, et al.
Publicado: (2023)

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
por: Salem, Riad, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells
por: As Sobeai, Homood M., et al.
Publicado: (2022)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Congenital cardiac liver cirrhosis with combined hepatocellular-cholangiocarcinoma—a case report
por: El Dika, Imane, et al.
Publicado: (2022)

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
por: Finn, Richard S, et al.
Publicado: (2022)

Effectiveness of Sorafenib in Hepatic Hemangioma
por: Tiwari, Prateek, et al.
Publicado: (2017)

Sorafenib as an Inhibitor of RUVBL2
por: Nano, Nardin, et al.
Publicado: (2020)

Sorafenib in Dupuytren and Ledderhose Disease
por: Schoenfeld, Joshua D, et al.
Publicado: (2022)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6htm0j1bu83ttbeat3nro482tb